DATA SHEET

For research use only. Not for use in humans.

Reagent: Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 (HJ16)

Catalog Number: ARP-12138

Lot Number: 170238

Release Category: C

Provided: Each vial of ARP-12138 contains approximately 100 micrograms of affinity purified antibody in sterile phosphate-buffered saline (PBS) at a concentration of 9.6 milligrams per milliliter. No preservatives were added.

Description: ARP-12138 is a recombinant monoclonal antibody to HIV-1 gp120. This antibody was produced in 293F cells and purified by protein A affinity chromatography.

Host or Host Site: Human

Special Characteristics: This antibody preferentially neutralizes Tier-2 HIV-1 variants. Epitope is conformational and located in the CD4 binding site.

The user should determine the optimal concentration for any application.

Recommended Storage: Keep at 4°C only for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Antonio Lanzavecchia

Isotype: IgG1 kappa

References:

Corti, D., et al. "Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals." U.S. Patent 1. PLoS One. 5 (2010): e8805. PubMed: 20098712.

Pietzsch, J., et al. "Human Anti-HIV-Neutralizing Antibodies Frequently Target a Conserved Epitope Essential for Viral Fitness." U.S. Patent 9. J. Exp. Med. 207 (2010): 1995-2002. PubMed: 20679402.

Citation: Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 (HJ16), ARP-12138, contributed by Dr. Antonio Lanzavecchia." Also include the references cited in any publications.

Biosafety Level: 1 Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers: You are authorized to use this product for research use only. It is not intended for use in humans.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

NIH HIV Reagent Program
www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org
Tel: 888-487-0727
Fax: 703-365-2898

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

Note:

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Antonio Lanzavecchia and Dr. Davide Corti, Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland at the following email address: davide.corti@irb.unisi.ch, before the reagent can be released.

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID

NIH HIV Reagent Program
www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org
Tel: 888-487-0727
Fax: 703-365-2898